Related Experiment Video
Updated: Mar 27, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
1.1K
Prognosis After Brain Metastasis from Differentiated Thyroid Carcinoma
Fumi Saito1, Takashi Uruno2, Hiroshi Shibuya2
1Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan. f-saito@ito-hospital.jp.
World Journal of Surgery
|January 15, 2016
Summary
Brain metastasis (BM) from differentiated thyroid carcinoma (DTC) is rare. Treatment for BM in DTC patients with good performance status and limited lesions can lead to longer survival.
Area of Science:
- Oncology
- Neurology
- Endocrinology
Background:
- Differentiated thyroid carcinoma (DTC) can metastasize to lungs and bones, but brain metastasis (BM) is exceptionally rare.
- Limited case reports exist on BM from DTC, leaving clinical characteristics and outcomes unclear.
Purpose of the Study:
- To clarify the clinical characteristics and prognostic factors for survival in patients with BM from DTC.
Main Methods:
- Retrospective review of 25 patients diagnosed with BM from DTC between 1965 and 2013.
- Analysis of prognostic factors including Karnofsky Performance Status (KPS), number of intracranial lesions, and treatment received for BM.
Main Results:
- The median age at BM diagnosis was 66 years, with 80% experiencing typical symptoms.
- Good KPS (≥70), fewer than four intracranial lesions (≤3), and treatment for BM were associated with longer survival on univariate analysis.
- Multivariate analysis identified treatment for BM as the only significant prognostic factor for survival.
Conclusions:
- Treatment for BM in DTC patients is recommended for those with good KPS and limited intracranial lesions.
- Selected patients with BM from DTC may achieve prolonged survival with appropriate treatment.
